Oculis Holding AG
NASDAQ:OCSBiotechnology
Healthcare
$7.39 -2.43%
-$0.28 today
- Market cap
- $456.20M
- Beta
- 0.13
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.61
52W Low $10.52High $34.48
Volume 0.31M
Average 0.65M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$79.15M
FY 2025 · Annual
Net Income
-$94.51M
FY 2025 · Annual
Income Statement
CHF
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 686K | 0 |
| Cost of Revenue | 0 | 0 | 0 | 52.08M | 0 |
| Gross Profit | 0 | 0 | 0 | (51.4M) | 0 |
| Gross Margin | — | — | — | -7492.3% | — |
| Research & Development | 9.57M | 22.22M | 29.25M | 52.08M | 54.52M |
| Selling, General & Admin | 4.1M | 6.74M | 14.72M | 21.81M | 24.63M |
| Operating Expenses | 13.23M | 32.38M | 80.71M | 21.81M | 79.15M |
| Depreciation & Amortization | 235K | 299K | 287K | 406K | 521.45K |
| EBITDA | (13.17M) | (31.9M) | (87.09M) | (85.53M) | (93.37M) |
| EBITDA Margin | — | — | — | -12468.1% | — |
| Operating Income | (13.23M) | (32.38M) | (80.71M) | (73.2M) | (79.15M) |
| Operating Margin | — | — | — | -10671.1% | — |
| Interest Income | 21K | 126K | 1.59M | 2.17M | 1.69M |
| Interest Expense | 5.12M | 6.44M | 1.46M | 639K | 795.55K |
| Other Income / Expenses | (5.29M) | (6.27M) | (7.98M) | (12.73M) | (15.54M) |
| Income Before Tax | (18.52M) | (38.64M) | (88.7M) | (85.94M) | (94.69M) |
| Pre-Tax Margin | — | — | — | -12527.3% | — |
| Income Tax Expense | 27K | 55K | 107K | (160K) | 177.64K |
| Net Income | (18.55M) | (38.7M) | (88.8M) | (85.78M) | (94.51M) |
| Net Margin | — | — | — | -12503.9% | — |
| EPS (Basic) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| EPS (Diluted) | (0.57) | (1.18) | (2.97) | (2.12) | (1.81) |
| 32.73M | 32.73M | 29.9M | 40.41M | 52.36M | |
| 32.73M | 32.73M | 29.9M | 40.41M | 52.36M |
OCS Earnings Waterfall · TTM
NASDAQ:OCS · Revenue to Net Income
Key Ratios
EPS$-1.73
Gross Margin-1378.1%
Net Margin-4164.6%
P/E Ratio-9.7
P/S Ratio1528.3
Analysis
$504.0K of revenue converted into -$95.1M of net income for the selected period. Gross margin is -1378.1% and net margin is -4164.6%, showing how much revenue survives after costs and taxes. EPS is $-1.73, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 3, 2026 | |
| 424B5 | 424B5 filing | Nov 3, 2026 | |
| 6-K | 6-K filing | Sep 30, 2026 | |
| 6-K | 6-K filing | Aug 10, 2026 | |
| S-8 | S-8 filing | Aug 6, 2026 |
How much revenue does OCS generate?
Oculis Holding AG (OCS) reported $0.00 of revenue in fiscal 2025.
Is OCS profitable?
Oculis Holding AG (OCS) reported -$94.51M of net income.
Continue the stock analysis
Jump to another research area for this company.